Acta Scientific Women's Health (ASWH)(ISSN: 2582-3205)

Review Article Volume 5 Issue 5

Need for Primary Prevention of Carcinoma Cervix: Barriers for HPV Vaccination and Experience in Implementing HPV Vaccination at a Tertiary Care Teaching Hospital in South India

Papa Dasari*

Senior Professor, Department of OBGY, WCH, JIPMER, Puducherry, India

*Corresponding Author: Papa Dasari, Senior Professor, Department of Obstretrics and Gynaecology, WCH, JIPMER, Puducherry, India.

Received: April 04, 2023; Published: April 20, 2023

Abstract

HPV vaccine, known generally as cancer vaccine has not been introduced in to the immunisation programme in India despite its implementation in more than 100 countries since 2009. It not only prevents the occurrence of carcinoma cervix but all other cancers such as oral, nasopharyngeal, anal and penile which are caused by HPV virus. The barriers for not implementing this vaccine are many such as unawareness of its benefits, myths regarding its side effects and lack of accountability on the part of health care administrators. The review presents the need for HPV vaccination and barriers for its implementation along with personal experience of its implementation in an Institute of National importance.

 Keywords: Carcinoma Cervix; CIN; HPV Vaccination; Barriers; Myths

References

  1. Nobel Prize.org. Nobel Prize Outreach AB (2022).
  2. Bruni L., et al. “ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre)”. Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019.
  3. Human Papilloma Virus and related Related Diseases report. INDIA.
  4. Human Papilloma Virus and related cancers, India. WHO/ICO, 3 red edition. Summary report Update June 22 (2010).
  5. Arbyn M., et al. “Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis”. Lancet Global Health2 (2020): e191-e203.
  6. Institute for Health Metrics and Evaluation. “The Challenge Ahead: Progress in Breast and Cervical Cancer”. Institute of Health Metrics and Evaluation (2011).
  7. Bobdey S., et al. “Burden of cervical cancer and role of screening in India”. Indian Journal of Medical and Paediatric Oncology 4 (2016): 278-285.
  8. Burd EM. “Human papillomavirus and cervical cancer”. Clinical Microbiology Review1 (2003): 1-17.
  9. Human Papillomavirus-Associated Cancers - United States, 2008-2012. CDC's Morbidity and Mortality Weekly Report, http://bit.ly/29ry5Ui.
  10. Reasons to get HPV Vaccine/CDC.
  11. Organization WH. Guidelines for the Prevention and Control of Cervical Cancer (2018).
  12. HPV Vaccine efficacy-CDC.
  13. Basu P., et al. “Vaccine efficacy against persistent human papilloma virus infection (HPV) 16/18 at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: A multicentre prospective cohort study”. The Lancet Oncology11 (2021): 1518-1529.
  14. Markowitz LE., et al. “Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses”. The Journal of Infectious Diseases 6 (2020): 910-918.
  15. Giuseppina Capra., et al. “Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily”. Human Vaccines and Immunotherapeutics8 (2017): 1839-1843.
  16. Aria C Attia., et al. “On surmounting the barriers to HPV vaccination: we can do better”. Annals of Medicine 3 (2018): 209-225.
  17. Healthy People 2020 national immunization goals. Washington State Department of Health website (2019).
  18. MILITARY MEDICINE, 185, 5/6:e878, 2020 Understanding Barriers to HPV Vaccination: Perspectives From Air Force Family Medicine Physicians and Active Duty Air Force Males Capt Courtney. E. Halista, MC, USAF*; Capt Randolph J. Kline, MC, USAF†; Lt Col Jennifer Bepko, MC, USAF (Ret.) (2020).
  19. Escoffery C., et al. “Facilitators and Barriers to the Implementation of the HPV VACs (Vaccinate Adolescents Against Cancers) Program: A Consolidated Framework for Implementation Research Analysis”. Preventing Chronic Disease 16 (2019): E85.
  20. Zheng L., et al. “Barriers to and Facilitators of Human Papillomavirus Vaccination Among People Aged 9 to 26 Years: A Systematic Review”. Sexually Transmitted Diseases12 (2021): e255-e262.
  21. HPV immunization coverage estimates among 15 years old girls.
  22. Bruni L., et al. “HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019”. Preventive Medicine 144 (2021): 106399.
  23. Arnheim-Dahlström L., et al. “Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study”. BMJ 347 (2013): f5906.
  24. Jefferson T and Jørgensen L. “Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction - a review of the regulatory evidence from the European Medicines Agency”. Indian Journal of Medical Ethics1 (2017): 30-37.
  25. Why Japan’s HPV vaccine rates dropped from 70% to near zero.
  26. Govt to provide cervical cancer vaccine to girls in schools.
  27. Dasari P., et al. “Health Education regarding Human Papilloma Virus (HPV Vaccine) for primary prevention of cervical cancer for parents of adolescent girls”. International Journal of Current Research and Review 20 (2015): 30-36.
  28. Gaffney DK., et al. “Too many women are dying from cervix cancer: Problems and solutions”. Gynecology and Oncology3 (2018): 547-554.
  29. Finlay Pilcher., et al. “Overcoming barriers to HPV vaccination in rural Vermont through a multicomponent peer-based approach”. Human Vaccines and Immunotherapeutics6 (2022).
  30. Senkomago V., et al. “CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide”. Emerging Infectious Diseases 13 (2017): S101-107.
  31. Sankaranarayanan R., et al. “Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study”. Vaccine32 (2018): 4783-4791.
  32. Man I., et al. “Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study”. The Lancet Oncology 11 (2022): 1419-1429.
  33. A second chance for the HPV vaccine.

Citation

Citation: Papa Dasari. “Need for Primary Prevention of Carcinoma Cervix: Barriers for HPV Vaccination and Experience in Implementing HPV Vaccination at a Tertiary Care Teaching Hospital in South India". Acta Scientific Women's Health 5.5 (2023): 33-41.

Copyright

Copyright: © 2023 Papa Dasari. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US